Cargando…

Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review

INTRODUCTION: Evidence from cardiovascular outcome trials (CVOTs) for newer antidiabetic drugs is increasingly influencing revised recommendations for second-line therapy in type 2 diabetes (T2D). This systematic review aimed to compare the cost-effectiveness of newer antidiabetic drugs specified as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Jiejin, Zhou, Ying, Li, Qingyu, Wang, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499965/ https://www.ncbi.nlm.nih.gov/pubmed/37515713 http://dx.doi.org/10.1007/s12325-023-02612-z

Ejemplares similares

Newer antidiabetic drugs and calorie restriction mimicry
por: Kalra, Sanjay, et al.
Publicado: (2016)

Red carpeting the newer antidiabetics
por: Gude, Dilip
Publicado: (2012)

A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
por: Laursen, Henrik Vitus Bering, et al.
Publicado: (2023)

Impact of Contextual-Level Social Determinants of Health on Newer Antidiabetic Drug Adoption in Patients with Type 2 Diabetes
por: Li, Yujia, et al.
Publicado: (2023)

Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients
por: Mudher Mikhael, Ehab
Publicado: (2016)

Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis
por: Batzias, Konstantinos, et al.
Publicado: (2018)

Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients
por: Palanisamy, Sivanandy, et al.
Publicado: (2018)

Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin
por: DeCarlo, Kristen, et al.
Publicado: (2022)

Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes
por: Heo, Chan Uk, et al.
Publicado: (2019)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Costs and Consequences Associated With Newer Medications for Glycemic Control in Type 2 Diabetes
por: Sinha, Anushua, et al.
Publicado: (2010)

Newer antithrombotic drugs
por: Sikka, Pranav, et al.
Publicado: (2010)

Ethnic and socioeconomic disparities in initiation of second‐line antidiabetic treatment for people with type 2 diabetes in England: A cross‐sectional study
por: Bidulka, Patrick, et al.
Publicado: (2022)

Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus
por: Liu, Wenhui, et al.
Publicado: (2022)

Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections
por: Sun, Bao, et al.
Publicado: (2021)

Adherence to Oral Antidiabetic Drugs in Patients with Type 2 Diabetes: Systematic Review and Meta-Analysis
por: Piragine, Eugenia, et al.
Publicado: (2023)

Type 1 diabetes research: Newer approaches and exciting developments
por: Sanjeevi, C. B.
Publicado: (2009)

Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus
por: Gutch, Manish, et al.
Publicado: (2017)

Drug resistance in leishmaniasis: Newer developments
por: Mohapatra, Sarita
Publicado: (2014)

Newer drug delivery systems in anesthesia
por: Dave, Sona, et al.
Publicado: (2017)

Are patients more adherent to newer drugs?
por: Blankart, Katharina E., et al.
Publicado: (2020)

The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth
por: Feng, Yin-Hsun, et al.
Publicado: (2011)

Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Gu, Shuyan, et al.
Publicado: (2022)

Comparative Efficacy of Novel Antidiabetic Drugs on Albuminuria Outcomes in Type 2 Diabetes: A Systematic Review
por: Liu, Geng, et al.
Publicado: (2023)

Diabetic nephropathy: newer therapeutic perspectives
por: Keri, Krishna C., et al.
Publicado: (2018)

Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States
por: Reifsnider, Odette S., et al.
Publicado: (2022)

Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management
por: Chaudhury, Arun, et al.
Publicado: (2017)

Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon: Erratum
Publicado: (2015)

Management of diabetes mellitus in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon
por: Sehgal, Vishal, et al.
Publicado: (2014)

Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus
por: Raparelli, Valeria, et al.
Publicado: (2020)

CAR T cell therapy: newer approaches to counter resistance and cost
por: Yadav, Rajesh Kumar, et al.
Publicado: (2020)

Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes
por: Vashisht, Rohit, et al.
Publicado: (2023)

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
por: Tzanetakos, Charalampos, et al.
Publicado: (2014)

Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents
por: Stoll, Felicitas, et al.
Publicado: (2022)

Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
por: Geethakumari, Praveen Ramakrishnan, et al.
Publicado: (2021)

Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis
por: Yu, Xiaofang, et al.
Publicado: (2018)

Newer goals!!!
por: Manohar, Balaji
Publicado: (2012)

The Newer Insulins
por: Morris, Noah
Publicado: (1940)

The Newer Antiseptics
Publicado: (1897)

Cannot write session to /tmp/vufind_sessions/sess_30vckd28s0dslqhbtmajquo9j1